Verastem Soars 16.58% on Positive NSCLC Trial Data

On August 14, 2025, Verastem's stock surged by 16.58% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Verastem Oncology recently announced a late-breaking abstract from a study conducted by its partner, GenFleet Therapeutics, which demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) patients at the recommended Phase 2 dose of 600 mg QD. This data is part of a phase 1/2 trial in China, focusing on NSCLC patients with a KRAS mutation.

Additionally, Verastem reported that the U.S. IND for VS-7375 has been cleared, and a Phase 1/2a trial has been initiated. This development is crucial as it paves the way for further clinical trials and potential approvals, which could significantly impact the company's future prospects.

The positive results from the GFH375 trial have been well-received by the market, contributing to the recent surge in Verastem's stock price. The company's focus on oncology and its innovative approach to treating NSCLC have positioned it as a key player in the biotech industry.